The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Incidence of Neuregulin1 (NRG1) gene fusions across tumor types.
 
Stephen V. Liu
Consulting or Advisory Role - ARIAD; AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; Ignyta; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Bayer; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Ignyta; Lycera; MedImmune; Merck; OncoMed; Pfizer; Threshold Pharmaceuticals
 
Rebecca Feldman
Employment - Caris Life Sciences
 
Hossein Borghaei
Honoraria - Bristol-Myers Squibb; Celgene
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Genmab; Lilly; Merck; Novartis; Pfizer; Trovagene
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - University of Pennsylvania
 
Shirish M. Gadgeel
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Pfizer
Speakers' Bureau - AstraZeneca
Research Funding - ACEA Biosciences (Inst); Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - ARIAD/Takeda; Genentech/Roche
 
Patrick C. Ma
Stock and Other Ownership Interests - Cymeta Biopharmaceutical
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Merck; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); Cymeta Biopharmaceutical (Inst); EpicentRx (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); OncoMed (Inst); Pfizer (Inst); Tesaro (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Jorge J. Nieva
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Turnstone Bio
Research Funding - Merck
 
Alexander I. Spira
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Ari M. Vanderwalde
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Millennium; Polynoma
Travel, Accommodations, Expenses - Caris Life Sciences
 
Antoinette J. Wozniak
Consulting or Advisory Role - ARIAD; Array BioPharma; AstraZeneca; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Coherus Biosciences; Epic; Hospira; Huron Consulting; HUYA Bioscience International; Quintiles; Takeda; WCCT Global
Research Funding - Boehringer Ingelheim
 
Sushma Jonna
No Relationships to Disclose
 
Edward S. Kim
Honoraria - AstraZeneca; Boehringer Ingelheim; Celgene; Lilly
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Lilly
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Celgene; Lilly